PATENT Case No. 21662P

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Susan P. Rohrer

Serial No.

10/594,372

Filed:

September 27, 2006

For: METHODS FOR THE TREATMENT OF

HYPERTENSION

To be assigned Art Unit: Examiner: To be assigned

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR 1.97**

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By Balrara Date 12-20-06



INFORMATION DISCLOSURE STATEMENT

8. 1.98(d), copies of references listed on the attached form that were submitted to or cited

by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are

	RELATED APPLICATION					
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE				
If this is inconvenient, additional copies will be submitted u	pon request.					
6. In accordance with 37 C.F.R. 1.97, (check one)	the filing date of the continued con					
the attached information is filed within three months of						
the attached information is filed more than three month Office Action on the merits.	s after the filing date but prior to the	mailing of a first				
the attached information is filed before the mailing of a examination under §1.114.	first Office action after the filing of a	request for continued				
the attached information is being filed more than three Office Action on the merits, but before the mailing date otherwise closes prosecution in the application. The en Account No. 13-2755 for the fee required under 37 C.F.	of a Final Action, Notice of Allowand nolosed authorization is therefore given	ce, or an action that				
each item of information contained in this Information E from a foreign patent office in a counterpart foreign app Statement.		-				
each item of information contained in the information d from a foreign patent office in a counterpart application designated in §1.56(c) more than thirty days prior to the	and this communication was not re-	ceived by any individu				
no item of information contained in this Information Dis- foreign patent office in a counterpart foreign application after making reasonable inquiry, was known to any indi- months prior to the filing of this Statement.	n, and, to the knowledge of the perso	on signing the certificat				
	Respectfully submitted,					
	By: Nicole M. Beeler	(le)				
•	•	plicant(s)				
	Reg. No. <u>45,194</u> MERCK & CO., INC.					
	Patent Dept., RY60-30					
	P.O. Box 2000 Rahway, N.J. 07065-09	07				

(732)594-1077

Date: December 20, 2006

•					·	Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE
	Substitute for form 1449A/PTO		COMPLETE IF KNOWN			
	IN	FORMATION :	MATION DISCLOSURE		Application Number	10/594,372
O PE STATEMENT BY APPLICANT			DITCANT	Filing Date	September 27, 2006	
			FLICANI	First Named Inventor	Susan P. Rohrer	
DEC 6 2006 3				•	Group Art Unit	To be assigned
use as many sheets as necessary)		Examiner Name	To be assigned			
100	Sheet	1	of	2	Attorney Docket Number	21662P
				*	***	·

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Docum Number		Name of Patentee or Applicant Oited Document Of Cited Document MM-DD-YYYY		

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
			WO 02/41835		Merck & Co., Inc.	05/30/2002		

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

Examiner Signature

	•				•	Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE
Substitute for form 1449B/PTO				COMPLETE IF KNOWN		
	INFORMATION DISCLOSURE			CLOSURE	Application Number	10/594,372
STATEMENT BY APPLICANT				DIICANT	Filing Date	September 27, 2006
				FLICANI	First Named Inventor	Susan P. Rohrer
				,	Group Art Unit	To be assigned
(use as many sheets as necessary)		Examiner Name	To be assigned			
<u> </u>	Sheet	2	of	2	Attorney Docket Number	21662P

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.					
		Zhu, Y, et al., Science, Vol. 295, pp 505-508, (2002), "Abnormal vascular function and hypertension in mice deficient in estrogen receptor B"					
		Ogawa, S, et al., Journal of Human Genetics, Vol. 45, pp 327-330 (2000), "Association of estrogen receptor B (ESR2) gene polymorphism with blood pressure"					
		Scuteri, A., et al., Annals of Internal Medicine, Vol. 135, No. 4, pp 229-238 (2001), "Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women"					
		Mirza, FS, et al., Endocrine Society Meeting, Philadelphia, PA, (2003), "Estradiol and angiotensin receptor blocker, irbesartan, have synergistic effect on blood pressure in postmenopausal hypertensive women"					
		·					
L		<u> </u>					

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.